Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
| Revenue (Most Recent Fiscal Year) | $152.31M |
| Net Income (Most Recent Fiscal Year) | $-80.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -47.72% |
| Net Margin (Trailing 12 Months) | -47.47% |
| Return on Equity (Trailing 12 Months) | -27.41% |
| Return on Assets (Trailing 12 Months) | -19.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.06 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.52 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 27.12M |
| Free Float | 22.62M |
| Market Capitalization | $345.24M |
| Average Volume (Last 20 Days) | 0.40M |
| Beta (Past 60 Months) | 2.36 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |